Disclosure of Value Transfers

Methodological Note

Country	Bulgaria
Entity Name	Medopharma EOOD
Legal Basis for Disclosure	Medicines for Europe Code of Conduct on Interactions with the Healthcare Community, published February 2015 Updated in January 2016
Reporting Period	2018
Currency of disclosed values	All values are disclosed in
Value identification and Recognition	All values disclosed are based on value transfers actually made within the respective category. Such value transfers have been made to a specific recipient as booked in the respective reporting period.
Multi-Year Contracts	Value transfers under multiyear contracts are part of the disclosed data to the extent that actual value transfers have been made in the respective reporting period.
Data disclosed	All values are disclosed for
for	☑ Recipients which have been engaged by entity
	☑ Recipients which have their residence in the country
VAT and other taxes	All amounts are disclosed include VAT or similar service taxes, where such apply on the transaction
Disclosure location:	http://bulgaria.medochemie.com/
Value category: "Meetings, educational support and site visits of HCPs"	The company discloses value transfers in this category as per Option 2 of the Medicine for Europe Transparency Requirements: Aggregate total amount of support provided to Healthcare Professionals per individual conference or meeting as follows:
	• Sponsorship for attending a third party organised congress (as per section 4.4):

Annex Document No.:

Version: Date of Publication: Date:

00

Page:

Disclosure of Value Transfers

	- name of congress,
	- aggregated amount spent for the congress, including the
	- number of Healthcare Professionals financially supported to attend
	• Site visits (as per section 4.5): aggregated amount spent, including the number of Healthcare Professionals financially supported to attend.
	• Company organised meeting: aggregated amount spent, including the number of Healthcare Professionals financially supported to attend.
Other Remarks	For value categories related to HCPs, aggregate values have been disclosed where the consent of a multiple number of HCP could not be obtained.
	Fees paid in connection with research & development activities or market research have not been disclosed.

Annex Document No.: Version: Date of Publication:

00

Date:

Page: